Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Pieris Pharmaceuticals Gmbh patents


Recent patent applications related to Pieris Pharmaceuticals Gmbh. Pieris Pharmaceuticals Gmbh is listed as an Agent/Assignee. Note: Pieris Pharmaceuticals Gmbh may have other listings under different names/spellings. We're not affiliated with Pieris Pharmaceuticals Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "P" | Pieris Pharmaceuticals Gmbh-related inventors


Engineered t cells and uses therefor

Lipocalin muteins specific to a predetermined antigen can be transduced into a t cell to bring therapeutic benefits to patients in need. In one example, a lipocalin mutein specific to a predetermined antigen (e.g., a target differentially expressed on the surface of a tumor cell) can be transduced into a t cell membrane to serve as an antigen receptor, offering benefits over conventionally deployed antibody-derived protein moieties such as a single chain variable fragment (scfv). ... Pieris Pharmaceuticals Gmbh

Novel proteins specific for angiogenesis

The present disclosure provides hngal muteins that bind ang-2 and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. ... Pieris Pharmaceuticals Gmbh

Human neutrophil gelatinase-associated lipocalin (hngal) muteins that bind hepcidin and nucleic acid encoding such

The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. ... Pieris Pharmaceuticals Gmbh

Tear lipocalin muteins binding il-4 r alpha

The present invention relates to novel muteins derived from human tear lipocalin, which bind to il 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. ... Pieris Pharmaceuticals Gmbh

Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation

The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition to a subject in need thereof, which composition contains a lipocalin mutein or a fragment or a variant thereof capable of increasing the bioavailability of iron in the subject.. . ... Pieris Pharmaceuticals Gmbh

Muteins of human lipocalin 2 (lcn2,hngal) with affinity for a given target

The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (lcn2, hngal) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. ... Pieris Pharmaceuticals Gmbh

Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors

The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of uniprot #p05112 and/or the ligand of uniprot #p35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the th2 immune response. ... Pieris Pharmaceuticals Gmbh

Novel specific-binding polypeptides and uses thereof

The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of swiss prot q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of swiss prot q9npf7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of swiss prot q16552 and swiss prot q9npf7. ... Pieris Pharmaceuticals Gmbh

Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3

The present invention relates to novel, specific-binding therapeutic and/or diagnostic lipocalin muteins directed against glypican-3 (gpc-3). The invention also relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. ... Pieris Pharmaceuticals Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Pieris Pharmaceuticals Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Pieris Pharmaceuticals Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###